Drugs / Luveris serono
Luveris serono
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT03204253 | Jan → Sep 2016 | female infertility | University of Roma La Sapienza | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Luveris serono | “Those patients received 75 iu of rLH (Luveris serono) daily and 150 iu about 12 hours before triggering ovulation with HCG” NCT03204253 ↗ |
| Known as | r-hLH | “The efficacy of recombinant human follicle-stimulating hormone (r-hFSH) for ovarian stimulation is well established however, the role of supplementary recombinant human...” NCT03204253 ↗ |
| Known as | r-LH | “Group A included 29 women stimulated with rFSH supplemented by rLH in the late follicular phase started at the same time of starting the antagonist administration.” NCT03204253 ↗1“rFSH + r-LH in combination” NCT03204253 ↗ |
| Known as | recombinant human luteinizing hormone | “The efficacy of recombinant human follicle-stimulating hormone (r-hFSH) for ovarian stimulation is well established however, the role of supplementary recombinant human...” NCT03204253 ↗ |
| Modality | Protein / enzyme biologic | “The efficacy of recombinant human follicle-stimulating hormone (r-hFSH) for ovarian stimulation is well established however, the role of supplementary recombinant human...” NCT03204253 ↗ |